Telli, T. Et Al. 2023. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with Lu-177-PSMA-617. A single-center prospective observational study. PROSTATE , vol.83, no.8 , 792-800.

Telli, T., Tuncel, M., Karabulut, E., Aksoy, S., Erman, M., Akdogan, B., ... Caglar, M.(2023). Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with Lu-177-PSMA-617. A single-center prospective observational study. PROSTATE , vol.83, no.8, 792-800.

Telli, Tugce Et Al. "Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with Lu-177-PSMA-617. A single-center prospective observational study," PROSTATE , vol.83, no.8, 792-800, 2023

Telli, Tugce Et Al. "Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with Lu-177-PSMA-617. A single-center prospective observational study." PROSTATE , vol.83, no.8, pp.792-800, 2023

Telli, T. Et Al. (2023) . "Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with Lu-177-PSMA-617. A single-center prospective observational study." PROSTATE , vol.83, no.8, pp.792-800.

@article{article, author={Tugce Telli Et Al. }, title={Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with Lu-177-PSMA-617. A single-center prospective observational study}, journal={PROSTATE}, year=2023, pages={792-800} }